8-K: Akoya Biosciences Reports Mixed Q1 2024 Results, Revenue Declines but Reagent Growth Continues

Akoya Biosciences' first quarter 2024 revenue decreased by 14% year-over-year to $18.4 million, though reagents and services revenue saw continued growth.

Summary

• Akoya Biosciences reported a 14% decrease in revenue for the first quarter of 2024, with total revenue reaching $18.4 million compared to $21.4 million in the same period last year.
• Despite the overall revenue decline, the company experienced continued growth in reagents and services revenue.
• The gross margin for the quarter was 46%, while the non-GAAP adjusted gross margin was 57% after excluding write-offs from discontinued legacy instruments.
• Operating expenses for the quarter were $30.0 million, with non-GAAP operating expenses at $25.6 million after excluding impairment and restructuring charges.
• The loss from operations was $21.6 million, and the non-GAAP loss from operations was $15.2 million, excluding certain charges.
• Akoya's installed base of instruments increased by 22% year-over-year, reaching 1,213 units.
• The company's publications citing their technology increased by 52% year-over-year, reaching 1,307.
• Akoya ended the quarter with $61.6 million in cash, cash equivalents, and marketable securities.
• The company has updated its full-year 2024 revenue outlook to a range of $104.0-$112.0 million, while maintaining its commitment to achieving operating cash flow breakeven by year-end.

Sentiment

Score: 4

Explanation: The document presents mixed results with a significant revenue decline and lowered guidance, offset by growth in installed base and publications. The sentiment is cautiously negative due to the financial underperformance.

Positives

• Reagents and services revenue continued to increase, indicating strength in core product offerings.
• The installed base of instruments grew by 22% year-over-year, demonstrating market adoption.
• The number of publications citing Akoya's technology increased by 52% year-over-year, highlighting the growing scientific validation of their products.
• The establishment of a new Manufacturing Center of Excellence is expected to scale internal reagent manufacturing.
• Partnerships with Acrivon Therapeutics, NeraCare, and Shanghai KR Pharmtech are progressing, expanding market reach and clinical applications.
• The company is maintaining its commitment to achieving operating cash flow breakeven by year-end.

Negatives

• Total revenue decreased by 14% year-over-year, falling short of expectations.
• Systemic pressure on capital expenditures impacted results.
• Certain pharmaceutical partner lab services revenue were deferred to the second half of 2024.
• The launch of the Manufacturing Center of Excellence temporarily impacted reagent fulfillment times, delaying instrument purchases.
• The company reported a GAAP loss from operations of $21.6 million for the quarter.
• The company has updated its full-year 2024 revenue outlook to a range of $104.0-$112.0 million, which is a reduction from previous guidance.

Risks

• Systemic pressure on capital expenditures could continue to impact future sales.
• The deferral of pharmaceutical partner lab services revenue could affect short-term financial performance.
• The company's ability to achieve operating cash flow breakeven by year-end is dependent on successful execution of its strategies.
• The company faces risks related to the commercialization of new products and partnerships.
• The company's financial performance is subject to various market and economic conditions.

Future Outlook

Akoya has updated its full-year 2024 revenue outlook to a range of $104.0-$112.0 million and maintains its commitment to achieving operating cash flow breakeven by year-end.

Management Comments

• While we made meaningful progress in advancing both our operational and clinical objectives, our first quarter results fell short of expectations due to three main factors.
• With the industrys leading installed base, normalization of pharmaceutical partner revenue in the second half of 2024, and now resolved reagent availability issues, we believe that our foundational initiatives will lead us back to strong top-line growth and achievement of our profitability objectives.

Industry Context

The announcement reflects the challenges faced by life science companies in the current economic environment, including pressure on capital expenditures and the impact of clinical trial timelines on revenue recognition. The company's focus on expanding its installed base and partnerships aligns with industry trends towards personalized medicine and spatial biology.

Comparison to Industry Standards

• Akoya's revenue decline of 14% contrasts with some other life science companies that have reported modest growth or flat revenue in the same period, suggesting Akoya may be facing specific challenges.
• The 22% growth in installed base is a positive sign, but the revenue decline indicates that the company is not yet fully monetizing its installed base.
• The 52% increase in publications citing Akoya's technology is a strong indicator of scientific validation, which is a key factor for adoption in the research community.
• Companies like NanoString Technologies and 10x Genomics, which also operate in the spatial biology space, have reported varying results, with some experiencing growth and others facing similar headwinds, highlighting the competitive and dynamic nature of the market.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and lowered guidance.
• Employees may be affected by the restructuring and reduction in force mentioned in the report.
• Customers may experience delays in reagent fulfillment due to the launch of the new Manufacturing Center of Excellence.
• Partners may be impacted by the revised clinical trial milestones and revenue deferrals.

Next Steps

• Akoya will host a conference call on May 13, 2024, to discuss its first quarter 2024 financial results.
• The company will focus on normalizing pharmaceutical partner revenue in the second half of 2024.
• Akoya will work to resolve reagent availability issues and scale production at the new Manufacturing Center of Excellence.

Key Dates

Keywords

Spatial Biology, Phenotyping, Reagents, Instruments, Revenue, Gross Margin, Operating Expenses, Financial Results, Partnerships, Clinical Data, Manufacturing, Biotechnology